| Dr Aishwarya Amol Patil, MD | |
|
6901 N 72nd St, Omaha, NE 68122-1709 | |
| (402) 343-4328 | |
| Not Available |
| Full Name | Dr Aishwarya Amol Patil |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 14 Years |
| Location | 6901 N 72nd St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366595449 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Methodist Hospital | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians Clinic Inc | 4880506062 | 497 |
News Archive
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.
DiFusion Incorporated announced today that the company has received a CE Mark and European clearance to market and implant its new CleanFuze antimicrobial orthobiologic polymer. "We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over five years and attaining this milestone represents significant value for our shareholders," commented DiFusion Cofounder and CEO Derrick Johns.
Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.
› Verified 1 days ago
| Entity Name | Physicians Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049156 PECOS PAC ID: 4880506062 Enrollment ID: O20031105000345 |
News Archive
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.
DiFusion Incorporated announced today that the company has received a CE Mark and European clearance to market and implant its new CleanFuze antimicrobial orthobiologic polymer. "We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over five years and attaining this milestone represents significant value for our shareholders," commented DiFusion Cofounder and CEO Derrick Johns.
Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.
› Verified 1 days ago
| Entity Name | Madonna Rehabilitation Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417045642 PECOS PAC ID: 0446164081 Enrollment ID: O20031118000079 |
News Archive
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.
DiFusion Incorporated announced today that the company has received a CE Mark and European clearance to market and implant its new CleanFuze antimicrobial orthobiologic polymer. "We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over five years and attaining this milestone represents significant value for our shareholders," commented DiFusion Cofounder and CEO Derrick Johns.
Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.
› Verified 1 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.
DiFusion Incorporated announced today that the company has received a CE Mark and European clearance to market and implant its new CleanFuze antimicrobial orthobiologic polymer. "We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over five years and attaining this milestone represents significant value for our shareholders," commented DiFusion Cofounder and CEO Derrick Johns.
Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aishwarya Amol Patil, MD 6901 N 72nd St, Omaha, NE 68122-1709 Ph: () - | Dr Aishwarya Amol Patil, MD 6901 N 72nd St, Omaha, NE 68122-1709 Ph: (402) 343-4328 |
News Archive
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.
DiFusion Incorporated announced today that the company has received a CE Mark and European clearance to market and implant its new CleanFuze antimicrobial orthobiologic polymer. "We are extremely gratified to announce European clearance of our CleanFuze line of antimicrobial spinal implants. This material has been in development for over five years and attaining this milestone represents significant value for our shareholders," commented DiFusion Cofounder and CEO Derrick Johns.
Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.
› Verified 1 days ago
Mr. Stuart Gordon Oxford, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 8309 Cass St, Omaha, NE 68114 Phone: 402-397-8891 Fax: 402-397-8892 | |
Andrew S. Lee, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 14863 Ellison Cir, Omaha, NE 68116 Phone: 402-354-4000 | |
Christopher W. Anderson, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 110 N 175th St Ste 2000, Omaha, NE 68118 Phone: 402-559-8600 Fax: 402-596-4410 | |
Dr. Wesley L. Smeal, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 17021 Lakeside Hills Dr., Ste 200, Omaha, NE 68130 Phone: 847-631-5664 | |
Ms. Angela Pugh, A Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 12020 Pacific St, Omaha, NE 68154 Phone: 800-259-0287 | |
Kristine S. Oleson, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6901 N 72nd St, Omaha, NE 68122 Phone: 402-572-2295 | |
Matthew Gregory Hahn, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2725 S 144th St Ste 212, Omaha, NE 68144 Phone: 402-637-0800 Fax: 402-637-0808 |